Tegoprazan vs. Placebo in Non-erosive Reflux Disease Tegoprazan vs. Placebo in Non-erosive Reflux Disease
Is tegoprazan, a novel, long-acting potassium-competitive acid blocker, superior to placebo in patients with non-erosive reflux disease?Alimentary Pharmacology & Therapeutics
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
More News: Acid Reflux | Drugs & Pharmacology | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Health | Potassium